Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection (PURPOSE 2)
Fáze 3, dvojitě zaslepená, multicentrická, randomizovaná studie k vyhodnocení účinnosti a bezpečnosti subkutánně podávaného dvakrát ročně dlouhodobě působícího lenacapaviru pro pre-expoziční profylaxi HIV u cisgender mužů, transgender žen, transgender mužů a genderově nebinárních lidí ≥ 16 let Věk, kteří mají sex s mužskými partnery a jsou ohroženi infekcí HIV
The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV-1 infection.
The primary objective of this study is to evaluate the efficacy of LEN for HIV-1 pre-exposure prophylaxis (PrEP) in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth at risk of HIV-1 infection.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
-
Buenos Aires, Argentina, 1072
- Hospital General de Agudos JM Ramos Mejia
-
Buenos Aires, Argentina, B7600
- Instituto de Investigaciones Clinicas Mar del Plata
-
Buenos Aires, Argentina, 1202
- Fundacion Huesped
-
-
-
-
-
Belo Horizonte - MG, Brazílie, 30130-100
- Unidade de Pesquisa Clinica em Vacinas (UPqVac) da Faculdade de Medicina da Universidade
-
Canela-Salvador, Brazílie, 40110-060
- Fundação Bahiana de Infectologia
-
Manauas, Brazílie, 69040-000
- Fundação de Medicina Tropical Doutor Heitor Vieira Dourado / Fundação Medicina Tropical do Amazonas - FMT/IMT/AM
-
Nova Iguaçu, Brazílie, 26030-380
- Hospital General de Nova Iguaçu - HGNI
-
Porto Alegre, Brazílie, RS 91350 200
- Grupo Hospitalar Conceição/ Hospital Nossa Senhora da Conceição S.A.
-
Rio de Janeiro, Brazílie, 21040-360
- Instituto Nacional de Infectologia Evandro Chagas / Fundação Oswaldo Cruz - INI FIOCRUZ
-
São Paulo, Brazílie, 01246-903
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
-
São Paulo, Brazílie, 04121-000
- Centro de Referência e Treinamento DST/AIDS
-
São Paulo, Brazílie, 06519-332
- Center for Management and Research. SPDM-Paulista Association for the Development of Medicine-Hospital São Paulo/Federal
-
-
-
-
-
Cape Town, Jižní Afrika, 7925
- Desmond Tutu Health Foundation
-
Johannesburg, Jižní Afrika, 2038
- Wits Reproductive Health and HIV Institute (Wits RHI)
-
Pretoria, Jižní Afrika, 87
- The Aurum Institute: Pretoria Clinical Research Centre
-
Soshanguvhe, Jižní Afrika, 0152
- Setshaba Research Centre
-
Tembisa, Jižní Afrika, 1632
- The Aurum Institute Tembisa CRC, Clinic 4
-
Vincent, Jižní Afrika, 5217
- FPD-DTHF Ndevana Commuity Research Site
-
-
-
-
-
Guadalajara C.P., Mexiko, 44160
- Centro de Investigacion Farmaceutica Especializada de Occidente S.C.
-
-
-
-
-
Barranco, Peru, 15063
- Asociacion Civil Impacta Salud y Educacion - Sede Barranco
-
Callao, Peru, 7006
- Instituto de Medicina Tropical "Daniel Alcides Carrion", Facultad de Medicina Humana, UNMSM
-
Iquitos, Peru
- Asociacion Civil Selva Amazonica
-
Lima, Peru, 15001
- Via Libre
-
Lima, Peru, 15088
- Asociacion Civil Impacta Salud y Educacion - Sede San Miguel
-
-
-
-
PR
-
San Juan, PR, Portoriko, 00717
- Ararat Research Center
-
San Juan, PR, Portoriko, 00909
- Centro Ararat- San Juan
-
-
-
-
Alabama
-
Birmingham, Alabama, Spojené státy, 35233
- UAB Sexual Health Research Clinic
-
-
California
-
Loma Linda, California, Spojené státy, 92354
- Loma Linda University Clinical Trial Center Clinic
-
Los Angeles, California, Spojené státy, 90069
- Mills Clinical Research
-
Los Angeles, California, Spojené státy, 90036
- Ruane Clinical Research Group Inc.
-
Los Angeles, California, Spojené státy, 90038
- UCLA CBAM Vine Street Clinic
-
Los Angeles, California, Spojené státy, 90059
- Charles R. Drew University of Medicine and Science (CDU) - Clinical Translational Research Center (CTRC)
-
Los Angeles, California, Spojené státy, 90502
- The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
Palm Springs, California, Spojené státy, 92262
- BIOS Clinical Research
-
San Diego, California, Spojené státy, 92103
- UCSD Anti Viral Research Center
-
San Francisco, California, Spojené státy, 94102
- Optimus Medical Group
-
San Francisco, California, Spojené státy, 94102
- Bridge HIV at the San Francisco Department of Public Health
-
-
Colorado
-
Aurora, Colorado, Spojené státy, 80045
- University of Colorado Clinical and Translational Research Centers (CTRC)
-
-
Connecticut
-
New Haven, Connecticut, Spojené státy, 06510
- Yale University, School of Medicine
-
-
District of Columbia
-
Washington D.C., District of Columbia, Spojené státy, 20009
- Whitman-Walker Institute Inc.
-
Washington D.C., District of Columbia, Spojené státy, 20017
- Washington Health Institute
-
-
Florida
-
Fort Lauderdale, Florida, Spojené státy, 33308
- Therafirst Medical Center
-
Fort Lauderdale, Florida, Spojené státy, 33316
- Gary Richmond, MD, PA
-
Ft. Pierce, Florida, Spojené státy, 34982
- Midway Immunology & Research Center, LLC
-
Jacksonville, Florida, Spojené státy, 32207
- CAN Community Health Clinic
-
Miami, Florida, Spojené státy, 33136
- University of Miami Miller School of Medicine Division of Infectious Disease Research - Converge Miami
-
Miami Gardens, Florida, Spojené státy, 33055
- CAN Community Health
-
Orlando, Florida, Spojené státy, 32803
- Orlando Immunology Center
-
Sarasota, Florida, Spojené státy, 34237
- CAN Community Health
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30303
- Emory University
-
Atlanta, Georgia, Spojené státy, 30308
- Emory University Hospital Midtown Infectious Disease Clinic
-
Atlanta, Georgia, Spojené státy, 30030
- The Hope Clinic at Emory University
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60613
- Howard Brown Health Center
-
Chicago, Illinois, Spojené státy, 60612
- RMR Core Center
-
Chicago, Illinois, Spojené státy, 60612
- University of Illinois at Chicago, Department of Medicine, Division of Infectious Diseases, Project WISH
-
-
Indiana
-
Indianapolis, Indiana, Spojené státy, 46202
- Indiana University Infectious Diseases Research
-
-
Kentucky
-
Lexington, Kentucky, Spojené státy, 40503
- Baptist Health Lexington
-
Louisville, Kentucky, Spojené státy, 40241
- Norton Infectious Disease Specialists
-
-
Louisiana
-
New Orleans, Louisiana, Spojené státy, 70119
- LSU-CrescentCare Sexual Health Center- New Orleans Community Health Center
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21287
- Johns Hopkins University School of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02215
- The Fenway Institute
-
-
Michigan
-
Berkley, Michigan, Spojené státy, 48072
- Be Well Medical Center
-
Detroit, Michigan, Spojené státy, 48202
- Henry Ford Hospital
-
-
Mississippi
-
Jackson, Mississippi, Spojené státy, 39202
- Open Arms Healthcare Center
-
-
Missouri
-
Kansas City, Missouri, Spojené státy, 64111
- KC CARE Health Center
-
-
New Jersey
-
Newark, New Jersey, Spojené státy, 07102
- St. Michael's Medical Center
-
Somers Point, New Jersey, Spojené státy, 08244
- South Jersey Infectious Disease
-
-
New York
-
New York, New York, Spojené státy, 10029
- Icahn School of Medicine at Mount Sinai- Mount Sinai Downtown
-
-
North Carolina
-
Chapel Hill, North Carolina, Spojené státy, 27514
- NC TraCS Institute - CTRC; University of North Carolina at Chapel Hill
-
Greensboro, North Carolina, Spojené státy, 27401
- Cone Health/Regional Center for Infectious Disease Research Center
-
Winston-Salem, North Carolina, Spojené státy, 27103
- Wake Forest University Health Sciences
-
-
Ohio
-
Cincinnati, Ohio, Spojené státy, 45267
- University of Cincinnati
-
Columbus, Ohio, Spojené státy, 43210
- The Ohio State University Wexner Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19104
- Penn Prevention Unit
-
Philadelphia, Pennsylvania, Spojené státy, 19107
- Philadelphia FIGHT Community Health Centers, Jonathan Lax Treatment Center
-
-
South Carolina
-
Charleston, South Carolina, Spojené státy, 29425
- Medical University of South Carolina, Infectious Disease Clinic
-
Columbia, South Carolina, Spojené státy, 29203
- Prisma Health-Midlands Clinical Research Unit
-
Greenville, South Carolina, Spojené státy, 29605
- Prisma Health Internal Medicine Clinic
-
-
Tennessee
-
Memphis, Tennessee, Spojené státy, 38105
- St Jude Children's Research Hospital
-
Memphis, Tennessee, Spojené státy, 38103
- Methodist University Hospital/University of Tennessee Health Science Center, Clinical Research Center
-
Nashville, Tennessee, Spojené státy, 37208
- Meharry Medical College Clinical and Transitional Research Center
-
-
Texas
-
Austin, Texas, Spojené státy, 78705
- Central Texas Clinical Research
-
El Paso, Texas, Spojené státy, 79915
- Centro San Vincente
-
Houston, Texas, Spojené státy, 77098
- The Crofoot Research Center, INC
-
Houston, Texas, Spojené státy, 77009
- UT Health Science Center at Houston
-
-
Washington
-
Seattle, Washington, Spojené státy, 98104
- Ofiice of Dr. Peter Shalit, MD
-
-
-
-
-
Bangkok, Thajsko, 10330
- King Chulalongkorn Memorial Hospital
-
Bangkok, Thajsko, 10400
- Ramathibodi Hospital, Mahidol University
-
Bangkok, Thajsko, 10330
- Institute of HIV Research and Innovation
-
Bangkok, Thajsko, 10330
- The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS research Centre
-
Chiang Mai, Thajsko, 50200
- Research Institute for Health Sciences, Chiang Mai University
-
Khon Kaen, Thajsko, 40002
- Srinagarind Hospital, Khon Kaen University
-
Nonthaburi, Thajsko, 11000
- Bamrasnaradura Infectious Disease Institute
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Key Inclusion Criteria:
Incidence Phase
-
CGM, TGW, TGM, and GNB who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV infection.
-
HIV-1 status unknown at screening and no prior HIV-1 testing within the last 3 months.
-
Sexually active with ≥ 1 partner assigned male at birth (condomless receptive anal sex) in the last 12 months and 1 of the following:
- Condomless receptive anal sex with ≥ 2 partners in the last 12 weeks.
- History of syphilis, rectal gonorrhea, or rectal chlamydia in the last 24 weeks.
- Self-reported use of stimulants with sex in the last 12 weeks.
Randomized Phase
- Negative local rapid fourth generation HIV-1/2 Ab/Ag, central fourth generation HIV-1/2 Ab/Ag, and HIV-1 RNA quantitative nucleic acid amplification testing (NAAT).
- Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min at screening according to the Cockcroft-Gault formula for creatinine clearance (CLcr).
Key Exclusion Criteria:
Incidence Phase
- Prior use of HIV PrEP (including F/TDF or F/TAF) or HIV postexposure prophylaxis (PEP) in the past 12 weeks or any prior use of long-acting systemic PrEP (including cabotegravir or islatravir).
- Prior recipient of an HIV vaccine or HIV broadly neutralizing antibody formulation.
Randomized Phase
- Acute viral hepatitis A, B or C or evidence of chronic hepatitis B or C infection.
- Severe hepatic impairment or a history of or current clinical decompensated liver cirrhosis.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF
Participants will receive the following for up to approximately 52 weeks:
Participants will receive oral LEN if SC injections are not available. |
Tablets administered orally without regard to food
Ostatní jména:
Administered via SC injections
Ostatní jména:
Tablets administered orally |
|
Experimentální: Randomized Blinded Phase: Placebo LEN + F/TDF
Participants will receive the following for up to approximately 52 weeks:
Participants will receive oral LEN placebo if SC injections are not available. |
Tablets administered orally
Ostatní jména:
Administered via SC injections Tablets administered orally |
|
Experimentální: LEN Open-Label Extension (OLE) Phase
Participants will be offered entry into LEN OLE Phase, following completion of primary analysis, if LEN demonstrates acceptable safety and efficacy in the Randomized Blinded Phase. Participants randomized to LEN will continue to receive SC LEN 927 mg, every 26 weeks (± 7 days), and have study visits every 13 weeks (± 7 days). Participants randomized to F/TDF will switch to SC LEN 927 mg on OLE Day 1, Week 26 and every 26 weeks thereafter. Participants will also receive oral LEN 600 mg on OLE Days 1 and 2. All participants in LEN OLE Phase will complete the phase, once LEN becomes available or the sponsor decides to discontinue the study, whichever happens first. After completing LEN OLE Phase or study discontinuation, participants will transition to local PrEP, including LEN or other options. If a participant exits early, they will complete an early study drug discontinuation (ESDD), be referred to local PrEP services if needed, and have a 30-day follow-up visit. |
Tablets administered orally without regard to food
Ostatní jména:
Administered via SC injections
Ostatní jména:
|
|
Experimentální: Pharmacokinetic (PK) Tail Phase
Participants who prematurely discontinue study drug during the Randomized Blinded Phase and participants that were randomized to LEN who choose not to continue in the LEN OLE Phase will transition to the PK Tail Phase. Participants will receive oral F/TDF (or Emtricitabine/Tenofovir Alafenamide (F/TAF) for US participants only) once daily for 78 weeks to cover the PK tail and complete visits every 13 weeks (+/- 7 days). Upon unblinding, participants who were randomized to F/TDF in the Randomized Blinded Phase who decline to participate in the LEN OLE Phase will complete the ESDD visit, transition to local HIV prevention services, and return for a 30-day follow-up visit. |
Tablets administered orally
Ostatní jména:
F/TAF tablets administered orally once daily
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)
Časové okno: Incidence Phase Screening Visit (Day 1)
|
bHIV per 100 PY in the Incidence Phase was calculated using RITA. The RITA incorporated HIV-1 testing results and recency assay testing results to estimate the bHIV. Recency assay testing was performed for participants in the All Screened Set found to have HIV-1 infection at the Incidence Phase Screening Visit as defined below. Participants were considered to have recent HIV-1 infection if the normalized optical density (ODn) was below 1.5 threshold using the Sedia limiting antigen avidity enzyme immunoassay (LAg-EIA) and the HIV-1 RNA (viral load) was > 75 copies/mL of blood. HIV-1 infection was defined as participants having at least one of the following central lab results at the Incidence Phase screening visit:
|
Incidence Phase Screening Visit (Day 1)
|
|
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to Background HIV (bHIV, Participants in All Screened Set)
Časové okno: Up to 149 weeks
|
HIV-1 incidence per 100 PY for LEN was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples. bHIV incidence per 100 PY in All Screened Set was estimated as described in outcome measure#1. |
Up to 149 weeks
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to F/TDF
Časové okno: Up to 149 weeks
|
HIV-1 incidence per 100 PY was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples. |
Up to 149 weeks
|
|
Randomized Blinded Phase: HIV-1 Incidence Among Participants Adherent to LEN
Časové okno: Up to 149 weeks
|
A participant was defined as adherent to LEN if they have received all per-protocol administrations of LEN within 28 weeks since the previous administration. The incidence of HIV-1 infection per 100 PY calculation is defined in outcome measure #2. |
Up to 149 weeks
|
|
Randomized Blinded Phase: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
Časové okno: First dose date up to 184 weeks
|
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily have a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. |
First dose date up to 184 weeks
|
|
Randomized Blinded Phase: Percentage of Participants Experiencing Grade 3 or Higher Laboratory Abnormalities
Časové okno: First dose date up to 184 weeks
|
Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post-baseline visit, up to and including the last exposure date for participants who permanently discontinued study drug, or the last available date in the database snapshot for participants who were still on treatment at the time of an analysis. The division of acquired immunodeficiency syndrome toxicity grading scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that do not meet the criteria for an abnormality of at least Grade 1. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 potentially life-threatening. Percentages were rounded off. |
First dose date up to 184 weeks
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Ředitel studie: Gilead Study Director, Gilead Sciences
Publikace a užitečné odkazy
Obecné publikace
- Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice-yearly lenacapavir PrEP in cisgender gay men, transgender women and men, and gender-diverse people (PURPOSE 2). Presented at: HIV Drug Therapy Glasgow; November 10-13, 2024; Glasgow, United Kingdom.
- Kelley CF, Acevedo-Quinones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, Brinson C, Brites C, Cahn P, Cantos VD, Clark J, Clement M, Creticos C, Crofoot G, Diaz RS, Doblecki-Lewis S, Gallardo-Cartagena JA, Gaur A, Grinsztejn B, Hassler S, Hinojosa JC, Hodge T, Kaplan R, Lacerda M, LaMarca A, Losso MH, Valdez Madruga J, Mayer KH, Mills A, Mounzer K, Ndlovu N, Novak RM, Perez Rios A, Phanuphak N, Ramgopal M, Ruane PJ, Sanchez J, Santos B, Schine P, Schreibman T, Spencer LY, Van Gerwen OT, Vasconcelos R, Vasquez JG, Zwane Z, Cox S, Deaton C, Ebrahimi R, Wong P, Singh R, Brown LB, Carter CC, Das M, Baeten JM, Ogbuagu O; PURPOSE 2 Study Team. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. N Engl J Med. 2025 Apr 3;392(13):1261-1276. doi: 10.1056/NEJMoa2411858. Epub 2024 Nov 27.
- Cespedes M, Das M, Hojilla JC, Blumenthal J, Mounzer K, Ramgopal M, Hodge T, Torres TS, Peterson C, Shibase S, Elliott A, Demidont AC, Callaghan L, Watson CC, Carter C, Kintu A, Baeten JM, Ogbuagu O. Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP). PLoS One. 2022 Jun 3;17(6):e0267780. doi: 10.1371/journal.pone.0267780. eCollection 2022.
- Cantos Lucio VD, Mngadi K, Supparatpinyo K, et al. From Breakthroughs to Backbones: The Evolving Landscape of HIV PrEP. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI 2026); February 22-25, 2026; Denver, CO. Abstract 129.
- Kwan TH, Chan DPC, Lee SS. Utilisation of HIV pre-exposure prophylaxis and preferences of alternative long-acting modalities among men who have sex with men in Hong kong: a cross-sectional study. BMC Public Health. 2025 Dec 26;26(1):361. doi: 10.1186/s12889-025-26025-5.
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Organické chemikálie
- Heterocyklické sloučeniny, 1 kruh
- Heterocyklické sloučeniny
- Heterocyklické sloučeniny, 2-prsten
- Heterocyklické sloučeniny, fúzované kroužek
- Farmaceutické přípravky
- Nukleové kyseliny, nukleotidy a nukleosidy
- Puriny
- Deoxycytidin
- Cytidin
- Pyrimidinové nukleosidy
- Pyrimidiny
- Organofosforové sloučeniny
- Nukleosidy
- Deoxyribonukleosidy
- Organofosfonáty
- Adenine
- Kombinace drog
- Tenofovir
- Emtricitabine
- Emtricitabin, tenofovir-disoproxil-fumarát, kombinace léčiv
- lenacapavir
- emtricitabine tenofovir alafenamid
Další identifikační čísla studie
Další identifikační čísla studie
- GS-US-528-9023
- DOH-27-102021-6681 (Jiný identifikátor: South African National Clinical Trial Registry)
- 2023 (Grant/smlouva NIH USA)
- 2023-001025-23 (Číslo EudraCT)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .